
<http://bio2rdf.org/drugbank:DB00061> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Pegademase bovine" ;
	<http://schema.org/description> "Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life." ;
	<http://schema.org/drugClass> "Enzyme Replacement Agents" ;
	<http://schema.org/url> "https://schemaorg.metadatacenter.org/drugbank/DB00061.html" ;
	<http://schema.org/administrationRoute> "intramuscular" ;
	<http://schema.org/availableStrength> <http://bio2rdf.org/drugbank_resource:d4c7a100dd9dac16dce453550375c347> ;
	<http://schema.org/clinicalPharmacology> "Used to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine, 2'-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:fe38491ea0c8f60781960e94e09c9fd5> ;
	<http://schema.org/dosageForm> "Injection, solution" ;
	<http://schema.org/interactingDrug> "DDI between Pegademase bovine and Pentostatin - Pegademase Bovine may diminish the therapeutic effect of Pentostatin. Pentostatin may diminish the therapeutic effect of Pegademase Bovine." ;
	<http://schema.org/legalStatus> "Approved" ;
	<http://schema.org/manufacturer> <http://bio2rdf.org/drugbank_resource:43def0612a2d9ed1ab40977a8d7204f8> ;
	<http://schema.org/mechanismOfAction> "Pegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination." ;
	<http://schema.org/nonProprietaryName> "Adenosine deaminase" , "Adenosine aminohydrolase" ;
	<http://schema.org/identifier> "drugbank:DB00061" ;
	<http://schema.org/sameAs> <http://www.rxlist.com/cgi/generic2/pegademase.htm> , <http://www.drugbank.ca/drugs/DB00061> , <http://www.drugs.com/cdi/pegademase-bovine.html> .

<http://bio2rdf.org/drugbank_resource:43def0612a2d9ed1ab40977a8d7204f8> a <http://schema.org/Organization> ;
	<http://schema.org/name> "Sigma tau pharmaceuticals inc" .

<http://bio2rdf.org/drugbank_resource:d4c7a100dd9dac16dce453550375c347> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "250 [iU]/mL Injection, solution form with intramuscular route" .

<http://bio2rdf.org/drugbank_resource:fe38491ea0c8f60781960e94e09c9fd5> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "4375.0" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Adagen 250 unit/ml vial" .
